A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Therapeutic Use
- Acronyms RELEASE MSS1
- Sponsors GW Pharmaceuticals; Jazz Pharmaceuticals Inc
- 29 Jun 2022 Status changed from recruiting to completed.
- 28 Jun 2022 According to Jazz Pharmaceuticals media release, the data from this study will be submitted for presentation at the future medical meeting.
- 28 Jun 2022 Results published in the Jazz Pharmaceuticals media release.